Specifically, clinical studies have shown that SLFN11-positive group (SLFN11 positive staining was defined as ≥15% staining of the tumor nuclei) is closely associated with longer progression-free survival; in vitro experiments have further confirmed that high SLFN11 expression enhances the sensitivity of cells to platinum drugs (DNA damaging agents), highlighting its potential as a response biomarker (16). Here, SLFN11 is linked to neoplasm.